BioCentury

7:00 AM GMT, Oct 15, 2007
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

BioVascular: Platelet mediation

Preventing vascular graft failure by pharmaceutical means is not an area that has seen much success, but BioVascular Inc. hopes its saratin can prevent the buildup of platelets inside blood vessels that often causes graft failure. The company expects interim data from a pair of European Phase I/II trials next year.

Saratin is a recombinant version of a 12-kD polypeptide derived from leech saliva that helps keep the blood vessel open after

Read the full 711 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.